Pfizer lifts annual profit outlook as Q2 results come ahead, shares gain

Published 05/08/2025, 11:58
© Reuters

Investing.com -- Pfizer posted second-quarter earnings and revenue that exceeded analyst estimates and raised its full-year profit outlook, pushing its shares over 3% higher in premarket trading. 

The pharmaceutical giant reported Q2 earnings per share (EPS) of $0.78, well ahead of the $0.57 consensus.

Revenue for the period increased by 10% to $14.7 billion, also topping expectations of $13.47 billion.

“Pfizer had another strong quarter of focused execution and we’re pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins," said Dr. Albert Bourla, Chairman and CEO of Pfizer.

The company raised its full-year adjusted EPS outlook by $0.10 at the midpoint, now guiding to a range of $2.90 to $3.10, compared to the $3.01 consensus.

Full-year revenue guidance was reaffirmed at $61.0 to $64.0 billion.

Pfizer said the revised profit outlook reflects strong results in the first half of the year, improved cost efficiency, a lower tax rate, and favorable currency moves.

It also factors in a one-time $1.35 billion R&D charge tied to a licensing deal with 3SBio, which is expected to reduce third-quarter EPS by about $0.20.

The company said its guidance already accounts for current tariffs and potential drug pricing actions following a letter from President Trump in late July.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.